Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3091 participants.

Also called NCT01541956

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,091 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01541956
Other papers using this trial's data
  • Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) Diabetes, obesity & metabolism, 2016-08 DOI, PubMed 27406394

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01541956. Randomized; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)
Intervention (Drug)
Metformin
Intervention (Drug)
vildagliptin
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01541956
Content hash
134e140dad379c075fa00c01f5575df54d52c66bfe2174b5737065c77b73c52a